Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma's strategy at J.P.

Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.

As its lead candidate advances into a late-stage trial for pulmonary arterial hypertension (PAH), Inhibikase Therapeutics has picked up a commercial leader with plenty of experience in the PAH space.

“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful ...

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...